Thrombolysis in myocardial infarction (TIMI) defined major bleeding (OR: 2.45, 95% CI: 1.45–4.12 P =. This research analysis consisted of 4 trials with a total number of 9010 participants. Odds ratios (OR) with 95% confidence intervals (CI) were used to represent the data following analysis. The analysis was carried out by the RevMan software version 5.4. Different categories of bleeding events and cardiovascular outcomes were assessed. Online databases including EMBASE, Cochrane Central,, MEDLINE and Web of Science were searched for English based publications comparing the use of apixaban added to DAPT for the treatment of patients with ACS. In this meta-analysis, we aimed to compare the bleeding outcomes observed with the addition of apixaban to DAPT for the treatment of patients with ACS. Apixaban, a new non-vitamin K antagonist, has been approved for use. However, the recurrence of thrombotic events, potential aspirin and clopidogrel hypo-responsiveness, and other limitations of DAPT have led to the development of newer oral anti-thrombotic drugs. ĭual anti-platelet therapy (DAPT) with aspirin and clopidogrel has been the mainstay of treatment for patients with acute coronary syndrome (ACS). This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The datasets generated during and/or analyzed during the current study are publicly available. The authors have no conflicts of interests to disclose. 2021 100:12(e25185).Īll named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.Īll data and materials used in this research are freely available. Increased bleeding events with the addition of apixaban to the dual anti-platelet regimen for the treatment of patients with acute coronary syndrome: a meta-analysis. How to cite this article: Jin J, Zhuo X, Xiao M, Jiang Z, Chen L, Shamloll Y. ∗Correspondence: Xiaojun Zhuo, Department of Cardiology, Hospital of Northwestern Polytechnical University, Xi an 710072, Shanxi, PR China (e-mail: ).Ībbreviations: ACS = acute coronary syndrome, DAPT = dual antiplatelet therapy, GUSTO = Global Use of Strategies to Open Occluded Arteries, ISTH = International society on thrombosis and hemostasis, MACEs = major adverse cardiac events, MI = myocardial infarction, TIMI = thrombolysis in myocardial infarction. ADepartment of Cardiology, The Fourth Hospital of Changsha, Changsha, HunanīDepartment of Cardiology, Hospital of Northwestern Polytechnical University, Xi an, ShanxiĬTongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, PR China.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |